<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21656">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01852812</url>
  </required_header>
  <id_info>
    <org_study_id>0476-520</org_study_id>
    <nct_id>NCT01852812</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Pharmacokinetics of MK-0476 in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)</brief_title>
  <official_title>A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old With Perennial Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and pharmacokinetics of MK-0476 in the treatment of
      Japanese pediatric participants with perennial allergic rhinitis (PAR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Adverse Event</measure>
    <time_frame>Up to 14 days after last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) of MK-0476 Chewable Tablets (CT) and MK-0476 Oral Granules (OG)</measure>
    <time_frame>Up to Day 28 after first dose of study drug</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>MK-0476 OG/1-5 year olds/4 or 12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 1 to 5 years old receiving MK-0476 OG for 4 or 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0476 CT/6-9 year olds/12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 6 to 9 years old receiving MK-0476 CT for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0476 CT/10-15 year olds/12 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 10 to 15 years old receiving MK-0476 CT for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0476 Oral Granules (OG)</intervention_name>
    <description>MK-0476 4 mg OG, taken once daily at bed time for 4 or 12 weeks</description>
    <arm_group_label>MK-0476 OG/1-5 year olds/4 or 12 weeks</arm_group_label>
    <other_name>montelukast sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0476 Chewable Tablets (CT)</intervention_name>
    <description>MK-0476 5 mg CT, taken once daily at bed time for 12 weeks</description>
    <arm_group_label>MK-0476 CT/6-9 year olds/12 weeks</arm_group_label>
    <arm_group_label>MK-0476 CT/10-15 year olds/12 weeks</arm_group_label>
    <other_name>montelukast sodium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight â‰¥ 8 kg

          -  Diagnosis of PAR and has symptoms of PAR at Visit 1

        Exclusion Criteria:

          -  Past or present medical history of asthma
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
